Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 9, 2003, Pages 1109-1114

  Ohning, G V ^a,c   Walsh, J H ^a   Pisegna, J R ^a   Murthy, A ^b   Barth, J ^b   Kovacs, T O G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b EISAI INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; PEPTONE; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; FEMALE; FOOD INTAKE; HEADACHE; HELICOBACTER PYLORI; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-ULCER AGENTS; BENZIMIDAZOLES; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; HUMANS; MALE; OMEPRAZOLE; POSTPRANDIAL PERIOD; TREATMENT OUTCOME;

EID: 0037514492     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01573.x     Document Type: Article

References (16)

1. Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 1999; 13(Suppl. 3): 3-10.
2. Ohning GV, Barbuti RC, Kovacs TOG, et al. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric secretion in subjects with Heliobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 701-8.
3. Fordtran JS, Walsh JH. Gastric acid secretion rate and buffer content of the stomach after eating. Results in normal subjects and in patients with duodenal ulcer. J Clin Invest 1973; 52: 645-57.
4. Maxwell V, Eysselein VE, Kleibeuker J, Reedy T, Walsh JH. Glucose perfusion intragastric titration. Dig Dis Sci 1984; 29: 321-6.
5. Williams MP, Sercombe J, Hamilton RE, et al. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy subjects. Aliment Pharmacol Ther 1998; 12: 1079-89.
6. Pantoflickova D, Dorta G, Jornod P, Blum AL. Antisecretory activity of PPIs. Gut 2000; 47(Suppl. 3): A64(Abstract).
7. Londong W, Londong V, Cederburg C, et al. Dose-response study of omeprazole on meal-stimulated gastric acid secretion and gastrin release. Gastroenterology 1983; 85: 1373-8.
8. Sharma BK, Walt RP, Pounder RE, Gomes MD, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 1984; 25: 957-64.
9. Gardner JD, Perdomo C, Sloan S, et al. Integrated acidity and rabeprazole pharmacology. Aliment Pharmacol Ther 2002; 16: 455-64.
10. Cloud ML, Enas N, Humphries TJ, et al. Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). Dig Dis Sci 1998; 43: 993-1000.
11. Dekkers CPM, Beker JA. Thjodleifsson B, et al. Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicenter study. Aliment Pharmacol Ther 1999; 13: 179-86.
12. Baisley KJ, Tejura B, Morocutti A, Miller NM, Warrington S. Rabeprazole 20 mg is more potent than esomeprazole 20 mg in control of gastric pH in healthy volunteers. Am J Gastroenterol 2001; 96(Suppl. 1): S48.
13. Wilder-Smith C, Claar-Nilsson C, Hasselgren G, Röhss K. Esomeprazole 40 mg provides faster and more effective acid control than rabeprazole 20 mg in patients with symptoms of GERD. Am J Gastroenterol 2001; 96(Suppl.): S45.
14. Johnson P, Perdomo C, Barth J, Jokubaitis L. The benefit/risk profile of rabeprazole, a new proton pump inhibitor. Eur J Gastroenterol Hepatol 2000; 12: 799-806.
15. Besancon M, Simon A, Sachs G, et al. Sites of reaction of the gastric H.K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997; 272: 22 438-46.
16. Williams MP, Blanshard C, Millison J, et al. A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects. Aliment Pharmacol Ther 2000; 14: 691-9.